Thank you for Subscribing to Cannabis Business Insights Weekly Brief
Cannabis Business Insights | Monday, May 25, 2026
Retail buyers learned the hard way that hemp wellness products can create as many customer complaints as repeat purchases. A tincture labeled “full spectrum” might contain inconsistent cannabinoid levels. A topical cream may arrive with no clear sourcing information attached to it. Lab reports exist, though often buried behind QR codes customers never scan. The result is familiar across wellness retail. Confused staff, cautious consumers and products that quietly disappear after one reorder cycle.
That tension shows up most clearly among older consumers. Many are not looking for cannabis culture or recreational positioning. They want relief for joint pain, interrupted sleep or stress that has settled into daily routine. THC sensitivity still shapes buying behavior, especially in regions where cannabis remains culturally uneasy territory. Products framed too loosely around “wellness” often lose credibility fast with this demographic because the questions become practical very quickly. How much THC is in it? Will it interfere with medication? Can it be used during the workday?
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
CBG products have gained traction partly because they sit inside that narrower consumer comfort zone. Retailers have noticed it. The appeal is less about cannabinoid novelty and more about predictability. Buyers evaluating CBG lines tend to focus on formulation details that consumers actually ask about at the counter. How the extract is sourced. Whether the topical contains supporting herbal ingredients. Whether the product relies entirely on isolate loading to create perceived potency.
Supply chain structure matters more than many brands admit. White-label manufacturing still dominates large sections of the hemp market, which leaves retailers with limited visibility once cultivation, extraction and formulation move through separate contractors. When potency questions surface or labeling inconsistencies appear, tracing accountability becomes difficult. Some buyers now scrutinize production flow almost as closely as the finished formulation itself. Third-party testing has become expected. Ingredient handling practices and batch consistency carry more weight.
Consumer education has become part of the retail workload too. Store associates are still spending time explaining the difference between CBD, CBG and psychoactive cannabis products to first-time buyers. That creates friction when vendors provide little usable product guidance beyond marketing language. Inexperienced consumers tend to abandon purchases quickly when explanations become vague or overly technical.
Four Winds Farm operates closer to an agricultural producer than a packaged wellness brand, which may explain some of its appeal within the CBG segment. According to its interview transcript, the company grows certified organic hemp, formulates many of its products internally and relies on third-party laboratory testing for cannabinoid verification and contaminant screening.
Its product line leans heavily toward non psychoactive CBG applications tied to inflammation support, stress management and sleep support rather than recreational positioning. The company also appears unusually involved in direct consumer education, particularly for customers unfamiliar with hemp products. For buyers trying to reduce retail confusion around cannabinoid wellness products, that level of production visibility and formulation control may carry more long-term value than aggressive cannabinoid marketing.
More in News